ELI LILLY AND COMPANY - FORM 8-K

PR Newswire/Les Echos/ 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 


                                        FORM 8-K
        
                                   Current Report
                       Pursuant to Section 13 or 15(d) of the 
                           Securities Exchange Act of 1934
           Date of Report (Date of earliest event reported):  July 8, 2013
                                ELI LILLY AND COMPANY
               (Exact name of registrant as specified in its charter)
        


       Indiana
(State or Other Jurisdiction 


      of Incorporation)

Lilly Corporate Center          001-06351             35-0470950
Indianapolis, Indiana    (Commission File Number)  (I.R.S. Employer
(Address of Principal                             Identification No.)
Executive Offices)
                                                        46285
                                                     (Zip Code)
        Registrant's telephone number, including area code: (317) 276-2000
                                    No Change
            (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

-  Written communications pursuant to Rule 425 under the Securities Act (17 CFR
   230.425)
-  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
   240.14a-12)
-  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
   Act (17 CFR 240.14d-2(b))
-  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
   Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.

(b)  On July 8, 2013, John Lechleiter, Ph.D., resumed his position as the
Company's chairman, president, and chief executive officer.  As previously
announced, Dr. Lechleiter had taken a medical leave of absence beginning on May
6, 2013.  Derica W. Rice, who served as acting chief executive officer during
Dr. Lechleiter's absence, will resume his position as executive vice president,
Global Services and chief financial officer. Ellen R. Marram, who served as
interim chairperson of the Board of Directors, will resume her position as the
board's lead independent director.  A copy of the press release issued by the
Company on July 8, 2013 is furnished as Exhibit 99.1.

(c)  The information required under this Item is provided in paragraph 5.02(b)
above and in the Company's definitive proxy statement for the 2013 annual
meeting of stockholders filed with the SEC on March 25, 2013 and is herein
incorporated by reference.

Item 9.01   Financial Statements and Exhibits

(d)  Exhibit 99.1  Press release issued by Eli Lilly and Company on July 8,
2013.

Exhibit No.       Description of Document
99.1              Press Release dated July 8, 2013
                                       SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
                                       ELI LILLY AND COMPANY
                                       (Registrant)
                                       By: /s/ Jamie E. Haney 
                                       Name:   Jamie E. Haney
                                       Title:  Assistant Secretary and Counsel
                                       Dated:  July 8, 2013
                                       EXHIBIT INDEX

Exhibit No.         Description of Document
99.1                Press Release dated July 8, 2013


                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Jul/09/2013 08:37 GMT